Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

hibitor, PCI-27483, is currently being evaluated in a multicenter Phase I/II randomized study in patients with locally advanced or metastatic pancreatic cancer. As planned, we have completed the Phase I portion of this Phase I/II trial and have successfully advanced to Phase II. In the Phase II portion of this study each pancreatic cancer patient will receive a maximum of 12 weeks of treatment with gemcitabine alone or gemcitabine plus PCI-27483. As of to date we have dosed 11 pancreatic cancer patients and the study continues enrolling in the randomized Phase II segment of the trial. We anticipate completing enrollment of 46 patients in the second half of 2011.
  • Histone deacetylase (HDAC) Inhibitor, PCI-24781, is the company's orally-bioavailable HDAC Inhibitor that disrupts DNA repair and contributes to tumor cell death. In 3 Phase I clinical trials, conducted in patients with hematologic or solid tumors, clinical response or control of tumor growth has been observed following single-agent therapy with our HDAC Inhibitor. Pharmacyclics' HDAC Inhibitor has demonstrated a good safety profile in approximately 90 patients treated so far; the main dose-limiting toxicity was a rapidly reversible thrombocytopenia, which we believe is related to the pharmacologic mechanism of action. The magnitude of thrombocytopenia can be attenuated by modification of the treatment schedule. The Phase II portion of our ongoing trial is continuing in patients with follicular and mantle cell lymphoma.  Results are anticipated in the second half of 2011. To date we have enrolled 7 follicular and 3 mantle cell patients; so far in this study 1 patient had a partial response and 4 patients have reported stable disease after 2 cycles.
  • The HDAC Inhibitor PCI-24781 has also shown synergy in preclinical testing with several approved cancer therapeutics. A Phase I/II trial in sarcoma patients is ongoing and is co-sponsored by prominent investigators at Massachuse
    '/>"/>

  • SOURCE Pharmacyclics
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
    2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
    3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
    4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
    5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
    6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
    7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
    8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
    9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
    10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
    11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... 3, 2015  CytomX, a biopharmaceutical company developing ... announced the promotion of several members of its ... who previously served as vice president of business ... senior vice president of corporate development and strategy. ... as the vice president of business development at ...
    (Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 ... its primary and secondary endpoints in a phase III ... (OIC) in adult patients with chronic non-cancer pain. Naldemedine ... (PAMORA). This is the third Phase III trial in ... Study results showed that a 0.2 mg ...
    (Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
    Breaking Medicine Technology:CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5
    ... NEW YORK, Feb. 2, 2011 Reportlinker.com announces that ... catalogue: US Prebiotics Industry ... report analyzes the US And European markets for Prebiotics ... is further analyzed by the following product segments: Mannan-Oligosaccharide ...
    ... Feb. 2, 2011 H. D. Smith recently announced ... strategic planning and business development, Robert Appleby to corporate ... vice president marketing.  These appointments are the latest organizational ... address evolving customer needs. Joseph ...
    Cached Medicine Technology:US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7H. D. Smith Aligns Leadership Positions to Fill Three Senior Roles 2
    (Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
    (Date:8/4/2015)... , ... August 04, 2015 , ... ... higher learning, announced today that its RN to BSN and Master of ... awarded full accreditation through June 2020 from the Commission on Collegiate Nursing ...
    (Date:8/4/2015)... ... August 04, 2015 , ... Lightning ... at its Denver facility that will usher in a new standard of sticker ... Labels more effectively meet its twin objectives of quality and quantity without ...
    (Date:8/4/2015)... Arbor, MI and Topeka, KS (PRWEB) , ... ... ... Information Network (KHIN) announced today their partnership to make the Isabel Symptom Checker ... Isabel Symptom Checker provides consumers a mechanism to check their symptoms in an ...
    (Date:8/3/2015)... SC (PRWEB) , ... August 04, 2015 , ... ... published the first-ever Guidelines for Oral-Systemic Thermography.* , The new internationally peer-reviewed Guidelines ... performance of dental and systemic health infrared imaging, in evaluating patients with dental-oral ...
    Breaking Medicine News(10 mins):Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Lightning Labels Installs State-of-the-Art Digital Press 2Health News:Lightning Labels Installs State-of-the-Art Digital Press 3Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 2Health News:Isabel Healthcare Partners with the Kansas Health Information Network, Inc. to Deploy Isabel Symptom Checker within the MyKSHealth eRecord Personal Health Record 3Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 2Health News:American Academy of Thermology (AAT) Publishes First-Ever Guidelines for Oral-Systemic Thermography 3
    ... EpiCept Corporation,(Nasdaq and OMX Nordic Exchange: EPCT) ... present a company overview at the BMO Capital,Markets ... at 11:00 a.m.,Eastern Time. The conference will be ... City on December 4th and 5th. Mr. Talley ...
    ... Ind., Nov. 28 Conseco, Inc. (NYSE:,CNO) said today that ... by Long Term Care Group, Inc. (LTCG) for certain,back-office functions ... Run-off segment. Conseco announced earlier this year that it was,considering ... will assume responsibility for the customer call center and the ...
    ... Special ... and exclusive performances from Cyndi Lauper, Indigo ... YORK, Nov. 28 SIRIUS Satellite Radio,(Nasdaq: SIRI ) today announced ... an exclusive broadcast event on SIRIUS OutQ,109, the nation,s first and only ...
    ... WASHINGTON, Nov. 28 Today, Lung Cancer,Alliance-Massachusetts ... Cancer. The Report Card gauges the progress being ... Massachusetts. LCA-MA is a chapter of,Lung Cancer Alliance ... cause of cancer deaths nationally, as,well as among ...
    ... hepatitis liver disease, study finds , , WEDNESDAY, Nov. 28 ... boost the number of clotting cells, called platelets, in ... researchers report. , The new drug is called eltrombopag, ... idiopathic thrombocytopenic purpura (ITP) were able to use the ...
    ... Risk of developing colorectal cancer is known to ... analysis of 26 studies, involving over 25,000 participants shows ... distinct patterns of genetic inheritance. A team of researchers, ... their findings today in Atlanta at the American Association ...
    Cached Medicine News:Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 2Health News:EpiCept Corporation to Present at the BMO Capital Markets 2007 Focus on Healthcare Conference 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 2Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 3Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 4Health News:Conseco to Implement Systems and Operational Solution From Long Term Care Group 5Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 2Health News:SIRIUS OutQ Honors International Day of AIDS Awareness 3Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2Health News:Drug May Help Reverse Clotting Deficiency 2Health News:Drug May Help Reverse Clotting Deficiency 3Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 2Health News:Genetic differences point to ethnic and racial disparities in colorectal cancer risk 3
    Designed to safely and easily removing a cataract nucleus, round serrated handle, dull finish....
    Round handle dull finish. For right handed surgeon....
    Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
    Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
    Medicine Products: